The company’s shares closed 3.83% higher at Tk149 on the DSE today, giving it a market capitalisation of Tk6,647 crore.
Beximco Pharmaceuticals PLC is set to enter the herbal medicine business through a wholly owned subsidiary, as the listed drug maker seeks to diversify its product portfolio and expand its presence in the healthcare market.
The company’s board approved the incorporation of a new entity, proposed to be named Beximco Pharma Nutraceuticals Ltd, at a meeting on 12 November, according to a disclosure filed with the Dhaka Stock Exchange (DSE) today (15 November).
The proposed subsidiary will manufacture and market herbal medicinal products, with an initial paid-up capital of Tk10 crore, fully subscribed by Beximco Pharmaceuticals.
Keep updated, follow The Business Standard’s Google news channel
It will have an authorised share capital of Tk100 crore, divided into 10 crore ordinary shares of Tk10 each.
However, incorporation and commencement of operations will depend on obtaining the necessary statutory and regulatory approvals.
The move comes as Beximco Pharma seeks to expand beyond its existing portfolio of conventional medicines. The company has been expanding its domestic and international operations while maintaining revenue and profit growth.
At the same meeting, the board approved the appointment of SM Rabbur Reza as a director and managing director (MD) of the company, effective immediately.
Beximco Pharma reported revenue of Tk1,466 crore in the July-September quarter of FY27, up 6% year-on-year. Net profit rose 8% to Tk260 crore, while earnings per share stood at Tk5.72.
Commenting on the quarterly performance, Beximco Pharma MD Rabbur Reza said the results reflected the underlying strength and resilience of the business despite ongoing macroeconomic challenges.
He said the company remained focused on delivering growth for shareholders while providing high-quality, affordable medicines to patients at home and abroad.
The expansion plan follows a strong FY26, when Beximco Pharma’s annual revenue crossed Tk5,000 crore for the first time. Revenue rose 15% year-on-year to Tk5,626 crore, while net profit increased 31% to Tk914 crore. Earnings per share stood at Tk20.17, and the board recommended a 60% cash dividend.
Domestic sales, which account for most of the company’s business, grew 15% to Tk5,164 crore in FY26, while export revenue rose 8% to Tk441 crore.
Beximco Pharma ranked second among listed pharmaceutical companies in Bangladesh in both revenue and profit in FY26, behind Square Pharmaceuticals.
The company’s shares closed 3.83% higher at Tk149 on the DSE today, giving it a market capitalisation of Tk6,647 crore.
According to its September shareholding report, sponsors and directors held 30.13% of the company, institutional investors 25.73%, foreign investors 26.96% and the general public 17.12%.
Source: The Business Standard
Read More at: csslbd.net
stock exchange dhaka
dhaka stock exchange live
dsebd news
dhaka stock exchange today
dhaka stock exchange market price
dhaka stock exchange index
dhaka stock exchange latest share price
dhaka stock exchange share price
dhaka stock exchange indices
bd share newspaper
bd share news
dhaka stock exchange ltd
www.dhaka stock exchange
dhaka stock
ঢাকা স্টক এক্সচেঞ্জ
dhaka stock exchange by trade code
stock bangladesh news
dsc stock exchange
dhaka stock exchange agm
dhaka stock exchange today market price